Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia

M. D. Bronstein, M. Knoepfelmacher, B. Liberman, R. Marino, O. A. Germek, A. V. Schally

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The effect of somatostatin (SRIF: 10 μg/min during 120 min) on serum prolactin (PRL) levels was studied in eleven patients with hyperprolactinemia of varying causes: 2 patients with acromegaly; 2 with primary hypothyroidism; 4 with prolactinoma and 3 with drug (sulpiride) induced hyperprolactinemia. During SRIF infusion, no significant change in PRL levels was observed in any of the 4 groups studied except in one female patient with a prolactinoma. The biological activity of SRIF was demonstrated by the significant inhibition (P < 0.05) of insulin levels seen in all 11 patients (52% fall in relation to basal) without simultaneous modification of glycemia. These data suggest that SRIF does not decrease PRL secretion in most patients with hyperprolactinemia.

Original languageEnglish (US)
Pages (from-to)271-274
Number of pages4
JournalHormone and Metabolic Research
Issue number6
StatePublished - Jan 1 1987
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia'. Together they form a unique fingerprint.

Cite this